Determination of vancomycin and daptomycin MICs by different testing methods for methicillin-resistant Staphylococcus aureus

Journal of Clinical Microbiology

Volumn 49, Issue 6, 2011, Pages 2272-2273

  Kruzel, Mark C ^a   Lewis, Cole T ^a   Welsh, Kerry J ^a   Lewis, Evan M ^a   Dundas, Nicola E ^a   Mohr, John F ^b   Armitige, Lisa Y ^c   Wanger, Audrey ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b CUBIST PHARMACEUTICALS INC   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; VANCOMYCIN;

AGAR MEDIUM; ANALYTICAL EQUIPMENT; ANTIBIOTIC SENSITIVITY; ARTICLE; AUTOMATION; BACTERIAL STRAIN; BACTERIUM ISOLATE; BLOOD CULTURE; BROTH DILUTION; CONTROLLED STUDY; EPSILOMETER TEST; INTERMETHOD COMPARISON; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; STRAIN DIFFERENCE;

ANTI-BACTERIAL AGENTS; DAPTOMYCIN; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS;

EID: 79957492708     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02215-10     Document Type: Article

References (15)

1. Baker, C. N., and F. C. Tenover. 1996. Evaluation of Alamar colorimetric broth microdilution susceptibility testing method for staphylococci and enterococci. J. Clin. Microbiol. 34:2654-2659.
2. CLSI. 2006. Performance standards for antimicrobial susceptibility testing. CLSI approved standard M100-S16. CLSI, Wayne, PA.
3. Hsu, D. I., et al. 2008. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections. Int. J. Antimicrob. Agents 32:378-385.
4. Lodise, T. P., et al. 2008. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob. Agents Chemother. 52:3315-3320.
5. Maclayton, D. O., K. J. Suda, K. A. Coval, C. B. York, and K. W. Garey. 2006. Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 μg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. Clin. Ther. 28:1208-1216.
6. Mason, E. O., et al. 2009. Vancomycin MICs for Staphylococcus aureus vary by detection method and have subtly increased in a pediatric population since 2005. J. Clin. Microbiol. 47:1628-1630.
7. Moise, P. A., G. Sakoulas, A. Forrest, and J. J. Schentag. 2007. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 51:2582-2586.
8. Prakash, V., J. S. Lewis., II, and J. H. Jorgensen. 2008. Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used. Antimicrob. Agents Chemother. 52:4528.
9. Rybak, M. J., et al. 2009. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin. Infect. Dis. 49:325-327.
10. Sader, H. S., et al. 2009. Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. Antimicrob. Agents Chemother. 53:4127-4132.
11. Sader, H. S., P. R. Rhomberg, and R. N. Jones. 2009. Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53:3162-3165.
12. Soriano, A., et al. 2008. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 46:193-200.
13. Steinkraus, G., R. White, and L. Friedrich. 2007. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin- susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J. Antimicrob. Chemother. 60:788-794. (Pubitemid 47434257)
14. Swenson, J. M., et al. 2009. Accuracy of commercial and reference susceptibility testing methods for detecting vancomycin-intermediate Staphylococcus aureus. J. Clin. Microbiol. 47:2013-2017.
15. Welsh, K. J., et al. 2010. Clinical characteristics, outcomes, and microbiologic features associated with methicillin-resistant Staphylococcus aureus bacteremia in pediatric patients treated with vancomycin. J. Clin. Microbiol. 48:894-899.